We are excited to announce that Janssen has become a Premium Partner of EFCNI, with the common goal to improve the care for newborns and their parents worldwide!

A few words from this new partner:

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Janssen is now adding maternal fetal medicine as an area of prominent unmet need. With this new partnership, EFCNI and Janssen aim to raise awareness of rare alloimmune diseases such as haemolytic disease of the foetus and newborn (HDFN), a condition where maternal and foetal blood types are incompatible which – in severe cases – leads to anaemia, jaundice, severe brain haemorrhage or even death of the newborn.

We look forward to working with Janssen to fight these threats to newborns and their parents!